DE60203263D1 - Pyrazolderivate gegen tgf überexprimierung - Google Patents

Pyrazolderivate gegen tgf überexprimierung

Info

Publication number
DE60203263D1
DE60203263D1 DE60203263T DE60203263T DE60203263D1 DE 60203263 D1 DE60203263 D1 DE 60203263D1 DE 60203263 T DE60203263 T DE 60203263T DE 60203263 T DE60203263 T DE 60203263T DE 60203263 D1 DE60203263 D1 DE 60203263D1
Authority
DE
Germany
Prior art keywords
overexprimation
derivatives against
against tgf
pyrazol derivatives
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60203263T
Other languages
English (en)
Other versions
DE60203263T2 (de
Inventor
Francoise Jeanne Gellibert
Neil Mathews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0102661A external-priority patent/GB0102661D0/en
Priority claimed from GB0119424A external-priority patent/GB0119424D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of DE60203263D1 publication Critical patent/DE60203263D1/de
Application granted granted Critical
Publication of DE60203263T2 publication Critical patent/DE60203263T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
DE60203263T 2001-02-02 2002-01-30 Pyrazolderivate gegen tgf überexprimierung Expired - Fee Related DE60203263T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0102661 2001-02-02
GB0102661A GB0102661D0 (en) 2001-02-02 2001-02-02 Compounds
GB0119424 2001-08-09
GB0119424A GB0119424D0 (en) 2001-08-09 2001-08-09 Compounds
PCT/EP2002/000938 WO2002066462A1 (en) 2001-02-02 2002-01-30 Pyrazole derivatives against tgf overexpression

Publications (2)

Publication Number Publication Date
DE60203263D1 true DE60203263D1 (de) 2005-04-21
DE60203263T2 DE60203263T2 (de) 2006-02-09

Family

ID=26245671

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60203263T Expired - Fee Related DE60203263T2 (de) 2001-02-02 2002-01-30 Pyrazolderivate gegen tgf überexprimierung

Country Status (8)

Country Link
US (1) US20040087623A1 (de)
EP (1) EP1355903B1 (de)
JP (1) JP2004521915A (de)
AR (1) AR035777A1 (de)
AT (1) ATE291020T1 (de)
DE (1) DE60203263T2 (de)
ES (1) ES2237671T3 (de)
WO (1) WO2002066462A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
WO2003055860A1 (en) * 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
EP2306788A1 (de) * 2001-12-26 2011-04-06 E. I. du Pont de Nemours and Company Iridiumverbindungen und mit damit hergestellte Einrichtungen
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217787D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
TW200417547A (en) * 2002-07-31 2004-09-16 Smithkline Beecham Corp Compounds
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
AU2003268156A1 (en) 2002-09-17 2004-04-08 Eli Lilly And Company Novel pyrazolopyridine derivatves as pharmaceutical agents
MXPA05002376A (es) 2002-09-18 2005-05-23 Pfizer Prod Inc Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf).
AU2003260810A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
EA200500378A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
EP1542995A1 (de) * 2002-09-18 2005-06-22 Pfizer Products Inc. Neue isothiazol- und isoxazolverbindungen als inhibitoren des transforming growth factor (tgf)
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
WO2004048381A2 (en) * 2002-11-22 2004-06-10 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
AU2003290734A1 (en) 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1615895A4 (de) * 2003-04-03 2007-11-07 Merck & Co Inc Biarylsubstituierte pyrazole als natriumkanalblocker
DK2918288T3 (da) 2006-10-03 2017-11-27 Genzyme Corp Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
AU2008281543A1 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as Raf inhibitors
US8063152B2 (en) * 2008-03-17 2011-11-22 The Goodyear Tire & Rubber Company Boron containing functionalizing agent
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
IN2014DN03049A (de) 2011-10-26 2015-05-15 Seattle Childrens Res Inst
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
CN103351333B (zh) * 2013-06-19 2015-08-26 临海市联盛化学有限公司 一种芳基吡啶衍生化合物及其制备方法
CN103351331B (zh) * 2013-07-16 2015-03-04 临海市联盛化学有限公司 一种海洋天然产物Echinoclathrine A的制备方法
KR20190077048A (ko) 2016-11-14 2019-07-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 3,4-비피리딜 피라졸 유도체, 그의 제조 방법 및 그의 의학적 적용
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
KR20220107180A (ko) * 2019-11-28 2022-08-02 오리고 바이오파마, 에스.엘. 형질전환 성장 인자-베타 수용체 i/alk5의 억제제로서의 벤질아미드 유도체
EP3978487A1 (de) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-chinolin-4-yl-pyrazol-1-yl)-acetamid-derivate als inhibitoren des transformierenden wachstumsfaktor-beta-rezeptors i/alk5

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288741A1 (en) * 1997-05-22 1998-11-26 G.D. Searle And Co. 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
EP1355903A1 (de) 2003-10-29
ATE291020T1 (de) 2005-04-15
WO2002066462A1 (en) 2002-08-29
AR035777A1 (es) 2004-07-14
ES2237671T3 (es) 2005-08-01
US20040087623A1 (en) 2004-05-06
EP1355903B1 (de) 2005-03-16
JP2004521915A (ja) 2004-07-22
DE60203263T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
DE60203263D1 (de) Pyrazolderivate gegen tgf überexprimierung
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
NO20042356L (no) Tioetersubstituerte imidazokinoliner
ATE425147T1 (de) Imidazolderivate
NO20035634D0 (no) Diamin-derivater
DK1458685T3 (da) Substituerede phenylderivater
DE60227853D1 (de) Substituierte Pyridinylamine
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
ATE333445T1 (de) Pyrazolderivate
DE60229891D1 (de) Vernebler
DE50206892D1 (de) Substituierte imidazotriazinone
ATE459598T1 (de) Sulfonamidderivate
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE335740T1 (de) Ringannelierte pyrazolderivate
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE60206558D1 (de) Beschichtung
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DE60216967D1 (de) Substituierte cyclohexanderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee